As part of the continuing effort to develop an effective HIV vaccine, we generated a poxviral vaccine vector (previously described) designed to improve on the results of the RV144 phase III clinical trial. The construct, NYVAC-KC, is a replication-competent, attenuated recombinant of the vaccinia virus strain NYVAC. NYVAC is a vector that has been used in many previous clinical studies but is replication deficient. Here, we report a side-by-side comparison of replication-restricted NYVAC and replication-competent NYVAC-KC in a nonhuman primate study, which utilized a prime-boost regimen similar to that of RV144. NYVAC-C and NYVAC-C-KC express the HIV-1 antigens gp140, and Gag/Gag-Pol-Nef-derived virus-like particles (VLPs) from clade C and ...
abstract: While as yet there is no vaccine against HIV/AIDS, the results of the phase III Thai trial...
The use of heterologous immunization regimens and improved vector systems has led to increases in im...
Background: Recombinant viruses based on the attenuated vaccinia virus strain NYVAC are promising HI...
As part of the continuing effort to develop an effective HIV vaccine, we generated a poxviral vaccin...
© 2019 Kibler et al.As part of the continuing effort to develop an effective HIV vaccine, we generat...
Background: In order to improve the immunogenicity of currently available non-replicating pox virus ...
The nonreplicating attenuated poxvirus vector NYVAC expressing clade C(CN54) HIV-1 Env(gp120) and Ga...
The nonreplicating attenuated poxvirus vector NYVAC expressing clade C(CN54) HIV-1 Env(gp120) and Ga...
UNLABELLED: We compared the HIV-1-specific cellular and humoral immune responses elicited in rhesus ...
Background: To enhance the induction of insert specific immune responses, a new generation of replic...
In a follow-up to the modest efficacy observed in the RV144 trial, researchers in the HIV vaccine fi...
In a follow-up to the modest efficacy observed in the RV144 trial, researchers in the HIV vaccine fi...
While as yet there is no vaccine against HIV/AIDS, the results of the phase III Thai trial (RV144) h...
The generation of vaccines against HIV/AIDS able to induce long-lasting protective immunity remains ...
In this investigation we have generated and defined the immunogenicity of two novel HIV/AIDS vaccine...
abstract: While as yet there is no vaccine against HIV/AIDS, the results of the phase III Thai trial...
The use of heterologous immunization regimens and improved vector systems has led to increases in im...
Background: Recombinant viruses based on the attenuated vaccinia virus strain NYVAC are promising HI...
As part of the continuing effort to develop an effective HIV vaccine, we generated a poxviral vaccin...
© 2019 Kibler et al.As part of the continuing effort to develop an effective HIV vaccine, we generat...
Background: In order to improve the immunogenicity of currently available non-replicating pox virus ...
The nonreplicating attenuated poxvirus vector NYVAC expressing clade C(CN54) HIV-1 Env(gp120) and Ga...
The nonreplicating attenuated poxvirus vector NYVAC expressing clade C(CN54) HIV-1 Env(gp120) and Ga...
UNLABELLED: We compared the HIV-1-specific cellular and humoral immune responses elicited in rhesus ...
Background: To enhance the induction of insert specific immune responses, a new generation of replic...
In a follow-up to the modest efficacy observed in the RV144 trial, researchers in the HIV vaccine fi...
In a follow-up to the modest efficacy observed in the RV144 trial, researchers in the HIV vaccine fi...
While as yet there is no vaccine against HIV/AIDS, the results of the phase III Thai trial (RV144) h...
The generation of vaccines against HIV/AIDS able to induce long-lasting protective immunity remains ...
In this investigation we have generated and defined the immunogenicity of two novel HIV/AIDS vaccine...
abstract: While as yet there is no vaccine against HIV/AIDS, the results of the phase III Thai trial...
The use of heterologous immunization regimens and improved vector systems has led to increases in im...
Background: Recombinant viruses based on the attenuated vaccinia virus strain NYVAC are promising HI...